Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sandeep Juneja
Animal Pharm's correspondent Dr Sandeep Juneja – who heads up the AnimalHealthIndia consultancy – looks at Zoetis as an example of an important lesson in attaining and maintaining leadership for animal health companies.
Strong underlying growth in economy, steady politics, an ever-growing consumption landscape and the increasing ease of doing business – animal health companies in India had all the right ingredients for a prosperous year in 2017. This has also spilled into 2018, says Animal Pharm correspondent Dr Sandeep Juneja.
Charlie Munger, a leading US investment guru and stock market expert once said: "Too little attention in economics [is given] to second-order and even higher-order effects. This defect is quite understandable because consequences have consequences and consequences of the consequences have consequences and so on."
According to the Animal Pharm M&A table for 2017, there have already been 13 deals in the animal feed and nutrition space in the first seven months of the year – representing nearly half of all the purchases made in the wider animal health sector. Dr Sandeep Juneja explores the reasons behind this heightened interest.
By the end of 2016, Pfizer could split its business in two. Head of AnimalHealthIndia consultancy and Animal Pharm correspondent Dr Sandeep Juneja imagines the consequences if Zoetis was to adopt the same strategy as its former parent company.